Pharmaceutical TechnologyOriginal article
FDA reduces monitoring time for Amgen’s Imdelltra infusions
RegulatoryapprovedImdelltraPositive
AI Analysis
Summary
The FDA approved an update to Imdelltra's prescribing information for Amgen, reducing the required monitoring time for ES-SCLC patients following their first two infusions.
Outcome Details
FDA approved update to prescribing information reducing recommended monitoring time for ES-SCLC patients after first two infusions
Importance:3/10
Sentiment:
0.60
FDA approvallabel updatepost-marketES-SCLCpatient convenience
Related Companies
Read the original article
Published by Pharmaceutical Technology on September 15, 2026 8:40 AM